Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.
Investigating CYP3A-mediated Drug-Drug Interactions With BTK Degraders
Advertisement
Advertisement
Trending on OncLive
1
Mirvetuximab Soravtansine/Carboplatin Improves ORR But Fails to Extend PFS in FRα-High Recurrent Ovarian Cancer
2
Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer
3
Tolerability and ILD Prevention Drive Second-Line Treatment Sequencing in HER2+ NSCLC
4
FDA Accepts sBLA for Subcutaneous Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL
5